Deregulated transcription factors in the emerging cancer hallmarks
Author | Hasan, Adria |
Author | Khan, Naushad Ahmad |
Author | Uddin, Shahab |
Author | Khan, Abdul Q. |
Author | Steinhoff, Martin |
Available date | 2025-04-16T05:09:34Z |
Publication Date | 2024-01-31 |
Publication Name | Seminars in Cancer Biology |
Identifier | http://dx.doi.org/10.1016/j.semcancer.2023.12.001 |
ISSN | 1044579X |
Abstract | Cancer progression is a multifaceted process that entails several stages and demands the persistent expression or activation of transcription factors (TFs) to facilitate growth and survival. TFs are a cluster of proteins with DNA-binding domains that attach to promoter or enhancer DNA strands to start the transcription of genes by collaborating with RNA polymerase and other supporting proteins. They are generally acknowledged as the major regulatory molecules that coordinate biological homeostasis and the appropriate functioning of cellular components, subsequently contributing to human physiology. TFs proteins are crucial for controlling transcription during the embryonic stage and development, and the stability of different cell types depends on how they function in different cell types. The development and progression of cancer cells and tumors might be triggered by any anomaly in transcription factor function. It has long been acknowledged that cancer development is accompanied by the dysregulated activity of TF alterations which might result in faulty gene expression. Recent studies have suggested that dysregulated transcription factors play a major role in developing various human malignancies by altering and rewiring metabolic processes, modifying the immune response, and triggering oncogenic signaling cascades. This review emphasizes the interplay between TFs involved in metabolic and epigenetic reprogramming, evading immune attacks, cellular senescence, and the maintenance of cancer stemness in cancerous cells. The insights presented herein will facilitate the development of innovative therapeutic modalities to tackle the dysregulated transcription factors underlying cancer. |
Sponsor | The study was supported by grant from the Medical Research Center (to Khan AQ; Grants MRC#0122-297, IRGC#06-NI-19-189), Hamad Medical Corporation, Doha, State of Qatar. |
Language | en |
Publisher | Elsevier |
Subject | Emerging cancer hallmarks, transcription factors Metabolic reprogramming, epigenetic reprogramming Senescence Therapeutic response |
Type | Article |
Pagination | 31-50 |
Volume Number | 98 |
ESSN | 1096-3650 |
Check access options
Files in this item
This item appears in the following Collection(s)
-
Laboratory Animal Research Center (Research) [127 items ]
-
Medicine Research [1673 items ]